SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

A sharp selloff without a confirmed company update is widely attributed by traders to options-expiration positioning and weakness across biotech, though claims of deliberate price manipulation remain speculation. The broader focus is SELLASs extended quiet period and the wait for REGAL Phase 3 updates, with bulls buying the dip and bears raising concerns about the prolonged silence and trial outlook.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Teslas rocket-thruster Roadster demonstration is driving discussion, with some traders impressed by the technology and others dismissing it as a costly gimmick unlikely to contribute meaningfully to earnings; speculation that the TeslaSpaceX showcase hints at a merger is also circulating. The initial enthusiasm faded as shares fell, fueling debate over whether the reveal has commercial value or is mainly a promotional stunt.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves selloff is dominated by worries that its debt-funded AI data-center expansion and high borrowing costs could strain refinancing and returns, with traders also citing insider stock sales. Some see the decline as overdone given AI demand, contracted capacity and Nvidias support, while others view the bond-market stress as a warning about the businesss financing risk; Jensen Huangs reassurance and bullish analyst views have fueled volatile rebounds.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is under pressure as traders focus on a tech and semiconductor selloff, with concerns about AI infrastructure debt, spending returns and persistent inflation and yields weighing on the Nasdaq. The community is split between bearish traders citing further downside and dip buyers looking for a rebound, while monthly options expiration is adding to the choppy trading.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is under pressure amid a broader neocloud and AI-infrastructure selloff, as CoreWeaves debt concerns and worries about rising financing costs and returns on AI spending weigh on the sector. Traders disagree over whether the decline signals deeper trouble or an oversold pullback, with bulls arguing Nebius has a stronger balance sheet and is being dragged down by association.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

The iPhone Duos rapid preorder sellout and extended delivery estimates are drawing attention, though traders debate whether they signal strong demand or reflect limited supply and manufacturing constraints. Reactions are mixed: some see the launch as bullish, while others focus on Apples high valuation and fading intraday gains.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

PLTRs decline is being discussed mainly as part of a broader tech and AI-market pullback amid inflation, interest-rate, oil, and geopolitical concerns, alongside debate over its valuation after a strong run. Bulls see a market-driven dip and cite the companys business momentum, while bears focus on its high valuation and risk of further downside.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCI is drawing attention after a sharp selloff amid broader AI and server-stock weakness, with traders pointing to worries about AI funding, customer exposure and the companys margins and cash flow. Reactions are split between calls that the decline is an oversold sector-driven move and concerns about SMCIs governance and persistent underperformance; the new CFO appointment is seen as a confidence boost by some but not enough to settle the debate.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOnes $1.25 billion zero-coupon convertible-notes offering is a focus as shares fall, with traders debating potential dilution and the rationale for raising capital despite existing cash reserves. Some view the funds as a low-cost source for buybacks or acquisitions, while others are concerned about dilution and cite broader tech-sector weakness as added pressure.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

NVAXs sharp decline is being linked by traders to a circulated report claiming an FDA setback for its flu/COVID combination trial, which many in the community say recycles an older, resolved issue. Citis reiterated Sell rating and weakness across vaccine stocks were also cited, while traders disputed the reports relevance and blamed algorithmic selling.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Arcutis Biotherapeutics Stock Surging Thursday?

Cantor Fitzgerald initiated Arcutis (ARQT) at Overweight with a $48 target, citing Zoryve's potential for $3.5B in peak sales.read more...

Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study

MRK's tulisokibart meets the phase IIb HS study's primary endpoint, with high and medium-dose regimens showing superiority over placebo at week 16.

Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?

Orchestra BioMed Holdings, Inc. (OBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

RHHBY's Lunsumio Combo Meets Goal in 2L Follicular Lymphoma Study

Roche's Lunsumio-Revlimid combo meets its study goal in second-line or later follicular lymphoma, improving PFS versus rituximab plus Revlimid.

Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?

Arcutis Biotherapeutics (ARQT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Here's Why You Should Add ARQT Stock to Your Portfolio Now

Arcutis raises its 2026 revenue guidance as Zoryve gains momentum, expands into younger patients and advances potential new indications.

Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen 

Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.


5 Biotech Stocks Worth Adding to Your Portfolio Now 

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector. 

Arcutis Biotherapeutics, Inc. (ARQT) Q2 Earnings and Revenues Surpass Estimates

Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of +22.22% and +6.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Viatris Gears Up to Report Q2 Earnings: What's in the Cards?

VTRS readies Q2 results as growth in key markets and brands may offset manufacturing and pricing headwinds across parts of its portfolio.

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.

Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Sees 400% Spike In Retail Buzz As Q4 Beat Fuels After-Hours Rally

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$28.27
Prev Close	$29.10
Open	$29.11
Dividend Yield	0.00%
50-Day Moving Average	$25.43
Beta	1.33
Avg. Volume	3.43M
PE Ratio	140.51

52-Week High	$31.77
52-Week Low	$19.30
Market Capitalization	$3.66B
EPS (Annual)	-$0.1269
Price to Book	16.57
Revenue Per Employee	$1.06M

Feed

News

Sentiment

Earnings

Fundamentals

Info

ARQT Fundamentals